One fail and one success, should it be accepted? [Regulatives / Guidelines]

posted by ElMaestro  – Belgium?, 2019-07-17 14:33 (460 d 11:09 ago) – Posting: # 20382
Views: 1,612

Hello ssussu,

» We did a BE trial using a partial replicated design(TRR,RTR,RRT), but it was fail to demonstrate BE because the Cmax of one subject after administration of test drug was too much higher than reference drug, and when excluding the data of this subject, the results showed bioequivalent. But actually there were no reason to exclude the data from this subject.
» And we conducted another BE trial, this time using full replicated design(TRTR,RTRT), and this time the result showed bioequivalent.
» What I want to ask is, whether the second trial which showed bioeuquivalent would be accepted by agency. Any suggestions about this if we want to convince the agency to accept the successful one?

Not all agencies would accept it without a very good justification. I am sure you have one since the trial was repeated.

Use the forum's private channel and I will ask a few q's for my own clarification and give you a push in the right direction if the agency is CFDA, USFDA, EMA, TGA, ANVISA, HC or PMDA :-D

I could be wrong, but...

Best regards,

R's base package has 274 reserved words and operators, along with 1761 functions. I can use 18 of them (about 14 of them properly). I believe this makes me the Donald Trump of programming.

Complete thread:

 Admin contact
21,162 posts in 4,410 threads, 1,476 registered users;
online 8 (0 registered, 8 guests [including 4 identified bots]).
Forum time: Tuesday 01:42 CEST (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz